Gastroenterology Research and Practice / 2013 / Article / Fig 3

Research Article

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo

Figure 3

Growth curves showed the proliferation of MHCC97H cells until 72 h by CCK-8 assay. NET-1shRNA, sorafenib, and combination of NET-1shRNA with sorafenib resulted in 14.6%, 19.3%, and 33.3% reduction of cell proliferation at 48 h, in 46.5%, 50.6%, and 66.3% reduction of cell proliferation at 72 h. ( compared with untreated group. * compared with combination group).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.